the organic solvent making up the carrier is preferably an intermediate polarity solvent , for example : an ethoxydiglycol or butylenes glycol , or propylene glycol , or glycerin in a proportion from 1 % to 99 % of the total composition in relation to its other components . acetone , acetonitrile , benzyl alcohol , butyldiglycol , dimethyl acetamide , dimethyl formamide , dipropylene glycol monobutyl ether , ethanol , isopropanol , methanol , ethylene glycol monoethyl ether , monoethyl acetamide , dipropylene glycol monomethyl ether , liquid polyoxyethylene - glycol , propylene glycol , 2 - pyrrolidone , including n - methylpyrrolidone , diethyelene glycol monoethyl ether , ethylene glycol , diethyl phtalate , and a mixture of at least two of them . the above composition can be supplemented by polyunsaturated essential fatty acids to improve the skin surface . polyunsaturated fatty acids omega 3 and omega 6 can be introduced by adding hemp seed oil ( cannabis sativa ) in a proportion that can range from 1 % to 15 % of the total composition or through natural substitutes such as : fish oil ( orange roughy ), borage oil ( borago officinalis ), coconut oil ( cocos nucifera ), kukui oil , sesame oil ( sesamum indium ), reconstituted synthetic agpi &# 39 ; s or natural extracts , eicopentaenoic acid ( epa ) and docosahexaenoic acid ( dha ), shea butter , olive oil ( olea europea ), canola oil , walnut oil , soybean oil , and anchusa oil ( echium plantagineum ), that can be added to the composition in the proportion of 1 to 99 %, more specifically 2 % to 50 % and preferably 5 % to 10 % of the total composition . the composition can also contain a soothing and / or anti - inflammatory and / or anti - pruriginous agent . preferably , the soothing agent is laureth 9 in the proportion of 0 . 8 % to 3 % or its substitutes , such as : menthol , and its salts , procaine , lidocaine , corticoids , by themselves or in combination of at least two of them . the laureth 9 polymer is a mixture of polyethylene glycol monolauric ethers with an average of 9 ethylene oxide groups per molecule . the anti - inflammatory agent can be bisabolol in the proportion of 1 % to 5 % or its substitutes : natural or synthetic azulene , allantoin , glycyrrhetinic 18 beta acid and its salts in the proportion of 0 . 01 % to 10 %, and preferably from 0 . 01 to 1 %, and aloe extracts , calendula extracts , carrot extracts , in the proportion of 0 . 01 to 10 %, and preferably from 5 to 10 %. the above composition contains an antioxidant and anti - radical product : tocopherol or vitamin e , in the form of tocopheryl acetate in the proportion of 0 . 2 % to 2 % or its substitutes , such as tocopheryl palmitate or tocopheryl linoleate . the composition also contains in combination with any one of the above compounds a thickening or stabilizing crystallization - inhibiting film - forming agent , such as polyvinyl pyrrolidone or a product chosen from the following group : hydroxymethyl cellulose , polyvinyl alcohols , vinyl acetate and vinyl pyrrolidone copolymers , polyethylene glycols , benzyl alcohol , mannitol , glycerol , sorbitol , polyoxyethylene sorbitan esters , lecithin , sodium carboxymethyl cellulose , acrylic derivatives such as methacrylates derived from polyesters of the trimethyl pentanediol / adipic acid type and others . the composition also contains an insect - repellent product , such as neem seed oil that is in fact azadirachta indica at 0 . 25 % of azadirachtin or its substitutes such as : castor oil ( ricinus communis ), diethyl toluamide and butyl acetylaminopropionate , dimethyl phtalate , ethyl hexanediol , natural and synthetic camphor , pyrethrum and derivatives ( pyrethum album ), and oil garlic ( allium sativum ). more generally , the composition under the invention can contain the following essential oils by themselves or in combination : rosmarinus officinalis in the proportion of 0 . 3 % to 0 . 9 % with a purifying and soothing sanitizing effect or eucalyptol . lavandula hybrida in the proportion of 0 . 3 % to 0 . 9 % or lavandula angustifolia with a deodorant effect . eugenia caryophyllus with an insect - repellent effect , in the proportion of 0 . 3 % to 0 . 9 %. melaleuca alternifolia or origan majorana in the proportion of 0 . 3 % to 0 . 9 % with an anti - infectious effect . cinnamorum camphora or camphor , in the proportion of 0 . 15 % to 0 . 6 % with a deodorant and anti - pruriginous effect . mentha piperita or mentha orvensis in the proportion of 0 . 15 % to 0 . 6 % with a deodorant effect . cedrus atlantica or sas libanus , in the proportion of 0 . 15 % to 0 . 6 % with an anti - parasitic , cicatrizant and anti - carcinogen effect . curcuma longa or curcuma zedoaria in the proportion of 0 . 15 % to 0 . 6 % that also has an anti - parasitic effect . origanum compactum or origonum vulgare , in the proportion of 0 . 06 % to 0 . 3 % with an insect - repellent and antimicrobial effect . gaultheria procumbens or its methyl salicylate substitute with a sedative and anti - pruriginous effect . synthetic musk or musk ketone , in the proportion of 0 . 06 % to 0 . 3 % to perfume or mask natural odors . the above compounds are used in combination in the composition under the invention based on the effects sought . more generally , the essential oils in the attached list can be combined in the composition under the invention . the essential oils were selected based on precise specifications with regard to the active ingredients they contain . among the active ingredients can be found in particular sesquiterpenes with anti - inflammatory properties , phenol compounds with locally immunostimulating and anti - infectious properties , other phenol compounds ( eugenol et carvacrol ) with insectifuge and repellent effects and esters with antalgesic and decongestant properties that may temper , even prevent , a possibly irritant action of the phenols on the skin . as carrier and skin solvent , an ethoxydiglycol . as vegetal oil rich in polyunsaturated fatty acids , hemp oil ( cannabis sativa ). as concentrated essential oils : rosmarius officinalis , lavendula hybrida , eugenia caryophyllus , melaleuca alternifolia , cinnamomum camphora , mentha piperita , cedrus atlantica , curcuma longa , origanum compactum , gaultheria procumbens , musk . as insect repellent and soothing product , neem seed extract ( azadirachta indica ) at 0 . 25 % of azadirachtin ). as soothing , desensitizing and anti - pruriginous ingredients , laureth 9 . as thickening , stabilizing crystallization - inhibiting agent forming a film on the animal skin , polyvinyl pyrrolidone as mentioned above in the description . a vitamin e with antioxidant function , such as d alpha tocopherol or tocopheryl acetate , or the products mentioned above in the description , or the products mentioned above ( other antioxidants ): butyl hydroxyanisole , butyl hydroxytoluene , ascorbic acid , sodium metabisulfate , propyl gallate , sodium thiosulfate , mixture of no more than two of them . an anti - inflammatory agent such as alpha - bisabolol , bisabolol or its substitutes as mentioned above in the description . the formulation active ingredients can be included in whole or in part in a “ delay ” formulation allowing for extended release time and thus extended action duration of these active ingredients . the compounds allowing for that modification can be chosen among beta - cyclodextrins , silica , cellulose fibers , nylon , poly - methacrylates . a delay or scheduled release formula can allow for extended release of the active ingredients up to twenty - eight days after application . the delay formulas use : beta - cyclodextrins , cyclic natural sugars : present in the formulation with a concentration ranging from 2 to 10 %. and / or cellulose fibers from wood : present in the formulation with a concentration ranging from 2 to 10 %. and / or polymethyl methacrylate and nylon spheres : present in the formulation with a concentration ranging from 4 à 12 %. and / or coated or non - coated silica microreservoirs : present in the formulation with a concentration ranging from 2 to 10 %. and / or linear polyester polymers with a molecular weight of 800 through 5000 daltons both occlusive and retentive : present in the formulation with a concentration ranging from 10 to 20 %. the proportions of each component are taken in the above - mentioned percentage values , said values being expressed in percentages of the total and full composition .
the invention relates to a dermo - cosmetic composition for pets . this composition includes a diffusion solvent vehicle that enables , by a simple application to one or more points of the cutaneous surface , a diffusion over the entirety thereof and at the level of the sebaceous glands . the active ingredients , primarily include a complex of essential oils and poly - unsaturated fatty acids , stored in the sebaceous glands , can be salted out progressively with the sebum product to the surface of the skin .